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Abstract 
Background: Alzheimer’s disease (AD) is the most common cause of dementia and its incidence is increasing 
worldwide along with population aging. Previous clinical and histologic studies suggest that the neurodegenerative 
process, which affects the brain, may also affect the retina of AD patients.
Main body: Optical coherence tomography (OCT) is a non‑invasive technology that acquires cross‑sectional images 
of retinal structures allowing neural fundus integrity assessment. Several previous studies demonstrated that both 
peripapillary retinal nerve fiber layer and macular thickness measurements assessed by OCT were able to detect neu‑
ronal loss in AD. Moreover, recent advances in OCT technology, have allowed substantial enhancement in ultrastruc‑
tural evaluation of the macula, enabling the assessment not only of full‑thickness retinal measurements but also of 
inner retinal layers, which seems to be a promising approach, mainly regarding the assessment of retinal ganglion cell 
layer impairment in AD patients. Furthermore, retinal neuronal loss seems to correlate with cognitive impairment in 
AD, reinforcing the promising role of OCT in the clinical evaluation of these patients.
Conclusion: The purpose of this article is to review the main findings on OCT in AD patients, to discuss the role of 
this important diagnostic tool in these patients and how OCT technology may be useful in understanding morpho‑
logical retinal changes in AD.
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Background
Alzheimer’s disease (AD) is the most common cause of 
dementia and its incidence is increasing worldwide asso-
ciated with population aging [1]. AD is characterized by 
progressive cognitive impairment, such as memory defi-
cit, decline in learning and executive functioning, apha-
sia, apraxia, agnosia and visual abnormalities [2, 3].
Visual complaints are common findings in AD patients 
and these may have an important impact on autonomy 
and quality of life of these patients. The most common 
visual symptoms are impairment of spatial contrast sensi-
tivity, motion perception, color discrimination and visual 
loss, which in the past, were attributed to lesions affect-
ing the primary visual cortex and other specific areas of 
the brain [3–6]. Neuroimaging techniques are essential 
in the diagnosis of AD and magnetic resonance imaging 
(MRI) has become the most used tool for cerebral imag-
ing in AD patients, providing detailed information about 
brain structure. The most common findings in MRI of 
patients with AD are atrophy in the medial temporal 
lobe, including hippocampus, amygdala, entorhinal cor-
tex and parahippocampal gyrus, ventricular enlargement 
and reduction of total brain volume [7]. Although stud-
ies have not yet completely elucidated the structural and 
functional changes that occur in brains of AD patients, 
some clinical and histologic studies suggest that the same 
neurodegenerative process that occurs in the brain, may 
also affect the retina, since the latter represents a periph-
eral part of central nervous system. Retinal pathological 
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changes such as loss of retinal ganglion cell (RGC) and 
their axons were demonstrated, both in animal models 
and in post mortem studies of human AD eyes [8–11]. 
Toxic aminoacids, such as fibrillar tau and Aβ aggregates 
were accumulated within the retina and its microvascula-
ture, and signs of neuroinflammation were present in the 
retina [12–16]. Therefore, according to several clinical 
and histologic studies there is strong evidence of anterior 
visual pathway impairment in AD patients, with pre-
dominant involvement of RGC and their fibers [10, 11, 
17–19].
Optical coherence tomography (OCT) is a non-inva-
sive technology, which acquires cross-sectional images of 
retinal structures allowing neural fundus integrity assess-
ment. Over the last years, OCT became the most widely 
used technology to detect and quantify structural axonal 
damage in many optic nerve and neurological diseases. 
Axonal loss is usually quantified by measuring OCT peri-
papillary retinal nerve fiber layer (RNFL) that allows an 
indirect estimation of RGC layer impairment. Further-
more, neuronal loss can be directly accessed by estimat-
ing macular thickness measurements, since 30–35  % of 
the retina thickness in macular area is composed by the 
RGCs and their fibers, as previously demonstrated in eyes 
with glaucoma, papilledema, compressive or demyelinat-
ing optic neuropathies [20–22]. If we take into account 
that the retina is considered a peripheral extension of the 
brain and both share similar embryological origin, it is 
easy to understand why OCT has become a widespread 
diagnostic tool in many neurological diseases.
Therefore, the purpose of this article is to address the 
main findings on OCT in AD patients, to discuss the 
role of this important diagnostic tool in these patients 
and how OCT technology could be useful to understand 
morphological retinal changes in AD.
Peripapillary retinal nerve fiber layer thickness 
in Alzheimer’s disease patients
The degeneration of the optic nerve and consequent loss 
of ganglion cells and their axons was first demonstrated 
histologically in patients with AD around 30  years ago 
[10]. Other studies confirmed these findings, revealing 
a predominant loss of the largest RGCs (M-cells) [11]. 
These post-mortem studies are clear evidence of anterior 
visual pathway impairment in AD patients. Hedges et al. 
[23] evaluated fundus photographs from 26 AD patients 
and found a high incidence of RNFL abnormalities.
With the advent of OCT, over the last two decades, it 
became possible to provide a directly clinical quantita-
tive assessment of retinal axonal loss. Several previous 
studies have evaluated the peripapillary RNFL thickness 
measurements assessed by OCT and all of them were 
able to demonstrate that most of RNFL parameters were 
reduced in patients with AD [19, 24–34]. The reduc-
tion of RNFL thickness was significantly greater than 
that which is observed in the age-matched controls and 
thus cannot be exclusively ascribed to aging. In accord-
ance with these studies, the reduction of RFNL thick-
ness occurred in each of the four retinal quadrants, 
suggest that axonal loss in patients with AD seems to 
be the result of a diffuse degeneration process of RGCs. 
Global reduction of peripapillary RNFL average thick-
ness measurements in AD patients was demonstrated by 
several independent groups [24, 28, 30, 31, 34]. Most of 
them observed a significant reduction of RNFL thickness 
in all quadrants [19, 24, 31, 35, 36], with a predominance 
in the superior [26–30] and inferior quadrants [24, 27, 
30]. Different groups showed the axonal loss with RNFL 
reduction in AD patients, despite different commercially 
available OCT devices used [37, 38].
Thomson et al. [39] conducted a systematic review and 
meta-analysis of the literature to determine the diagnos-
tic utility of OCT of the RNFL thickness measurements 
in various dementias, but focused predominantly in 
patients with AD and mild cognitive impairment (MCI). 
They included studies published until September 2014. 
They identified a total of 17 studies including 702 AD 
eyes and 790 control eyes. There was a significant reduc-
tion in the overall, inferior and temporal RNFL thickness 
measurements in AD patients compared with controls, 
regardless of whether time domain (TD) or spectral 
domain (SD) OCT was used. The nasal and temporal 
quadrants are only found to be significantly thinner in 
few studies. These authors concluded that studies ana-
lyzed in the systematic review suggest that the significant 
thinning of the RNFL does occur in AD, and that OCT 
can be successfully used to detect these changes.
In our review, we identified a total of 23 studies includ-
ing 1330 AD eyes, 326 MCI eyes and 1082 control eyes. 
In nine studies TD-OCT was used and in the other four-
teen, the patients were evaluated by SD-OCT. Seven 
studies included MCI [25, 28, 34, 35, 40–42] patients and 
others nine evaluated macular parameters [24–26, 31, 35, 
40, 43–45]. Table  1 summarizes the demographic data 
and RNFL thickness measurements in Alzheimer’s dis-
ease, MCI and controls by OCT.
Macular thickness measurements in Alzheimer’s 
disease patients
Since the RGCs layer and their axons contribute with 
approximately one-third of the total retinal thickness in 
macular area, macular thickness measurements assessed 
by OCT can be used to investigate neuronal loss in AD 
patients. This approach in AD evaluation is promising, 
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first because RGC’s and their fibers are located in macu-
lar area, which in accordance with previous histopatho-
logical studies, are preferably affected in AD [8, 9, 17], 
and secondly, because of the significant improvements 
occurred in the latest OCT’s equipments, evolving from 
time-domain (TD) to spectral fourier domain technology 
[52]. These improvements on OCT technology provide 
three-dimensional high-quality images with greater res-
olution, with an axial resolution up to five times higher 
and imaging speeds approximately 60 times greater than 
earlier TD OCT [53, 54]. This high-density raster retinal 
tissue scanning allow to detect and segment the retinal 
structures in each raster OCT image and use these data 
to construct a detailed macular map, with separate analy-
sis of different retinal layers [52].
Full thickness macular measurements
Iseri et al. [26] were the first group to assess both mac-
ular thickness and volume by TD-OCT of 28 eyes of 
14 patients with AD. The retinal thickness in all macu-
lar quadrants of AD patients was lower than in control 
subjects and reached statistical significance in the nasal, 
temporal and inferior quadrants, as well to the mean 
total macular volume. Moschos et al. [33] also evaluated 
the macular parameters using TD-OCT in AD patients. 
They demonstrated a preferential involvement of the cen-
tral macular area.
In SD-OCT era, Polo et  al. [45] evaluated macular 
area by SD-OCT of 75 AD patients and 75 age-matched 
healthy subjects. Retinal thinning was observed in AD 
eyes in all areas except from the fovea. In other study, 
Gao et al. [25] evaluated 25 patients with AD and found a 
significant reduction of macular volume in these patients. 
Salobrar-Garcia et  al. [50] also demonstrated a pref-
erential reduction of macular parameters in mild-AD 
patients. In this study, the peripapilary RNFL thickness 
was thinner, but did not reach a significant difference 
compared with age-matched controls, suggesting a pref-
erential involvement of the macula in early stages of the 
disease.
In a recently published study [24], we have evaluated 45 
eyes of 24 patients with AD using SD-OCT. Our results 
showed that the macula full-thickness measurements 
were significantly reduced in all segments, except in the 
inferior outer segment. The inner segments, around the 
fovea, were the most affected (Figs.  1, 2). This was an 
interesting finding and possibly indicates a pattern of 
neuronal loss in patients with AD. In agreement with our 
findings, Blank et al., in a histologically analysis, observed 
a total decrease of one quarter of neurons in GCL at the 
level of the fovea and parafoveal area of the retina in AD 
patients [9].
Inner retinal layers in Alzheimer’s disease patients
In the last decade, the spectral OCT technology evolved 
significantly allowing for creating high-resolution cross-
sectional images. The acquisition speed in SD-OCT 
reduced the time to acquire three-dimensional images 
with higher resolution, enhancing the ultrastructural 
macula analysis, enabling the assessment not only of full 
macular thickness measurements but also of inner reti-
nal layers. These layers are of particular interest in many 
ocular and neurological diseases and recent studies based 
on OCT measurements have demonstrated that the pres-
ence of RGC loss may be an early indicator of neural 
loss in many conditions, such as glaucoma, papilledema, 
compressive optic neuropathy, multiple sclerosis and 
optic neuromyelitis [55–58]. This approach may be 
promising in AD evaluation, especially because the RGC 
impairment shares similarities with neuronal loss in the 
brains of these patients. In fact, the reduction of full mac-
ular thickness, as shown in previous studies, is possibly 
related to the preferential involvement of the ganglion 
cell layer (GCL) [25, 26, 33, 45].
In 2013, Marziani et  al. [31] using SD-OCT, demon-
strated a reduction of RNFL + GCL thickness in the nine 
ETDRS subfields map in AD patients compared with 
age-matched controls. With the same SD-OCT, another 
group [43] demonstrated that the average, superior and 
inferior GCL thickness of the AD patients were signifi-
cantly thinner than those of the controls. Cheung et  al. 
[59] showed a significantly reduced macular ganglion 
cell-inner plexiform layer thicknesses in all macular 
sectors in AD patients compared with cognitively nor-
mal controls. In our study [24], the inner macular layers 
thickness measurements were automatically registered in 
a square pattern (6 × 6 mm). In each B-scan, the bounda-
ries between the anatomical inner retinal layers in macu-
lar area were automatically delimited by built-in software 
(Fig. 3). The parameters registered in this study were: the 
average of macular retinal nerve fiber layer (mRNFL) 
thickness, the average of GCL plus the inner plexiform 
layer (IPL) thickness, referred as GCL+ and the aver-
age of RNFL plus GCL+ thickness, referred as GCL++ 
(Fig. 3). A pseudo-color thickness map of these layers is 
shown in Figs. 2 and 3. Our results demonstrate that the 
GCL+ and GCL++ thickness were significantly lower 
in eyes of AD patients. The mRNFL thickness measure-
ments in AD eyes were lower than in control eyes, but 
did not reach statistical significance. Our results dem-
onstrated that inner retinal layers impairment reflect the 
neuronal degeneration of the retina in AD patients, pre-
dominantly affecting the central macular area.
So, as previously demonstrated, the inner retinal lay-
ers seem to be preferentially affected in AD. However, 
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information about the integrity of the other retinal layers 
is crucial. Recent advances in the SD-OCT technology, 
particularly with improvements in segmentation software 
analysis, may allow the measurement of all retinal layers. 
In a recently published study, Garcia-Martin et  al. [51], 
using an automatic segmentation prototype, showed that 
not only inner retinal layers were reduced in AD patients, 
but the outer nuclear layers were also impaired. Studies 
are needed in order to verify the clinical significance of 
this finding in AD patients and if it’s an indicative of a dif-
fuse degenerative process affecting all retinal layers or as 
result of retrograde transinaptic degeneration.
Correlation between RNFL and macular thickness 
measurements with the cognitive impairment 
in Alzheimer’s disease patients
Some of the crucial approaches for diagnosis of AD are 
based on neuropsychological tests such as the mini-men-
tal state examination (MMSE) scores, which are widely 
used to evaluate the cognitive impairments in dementia 
patients [2]. So, since the measurement of the degree of 
severity of cognitive impairment can be given by MMSE 
score, it seems reasonable that the correlation between 
this psychological test and OCT parameters could be 
useful information for clinical evaluation and monitoring 
of these patients.
In fact, some previous studies have evaluated the cor-
relation between OCT and MMSE score, but the results 
are somewhat conflicting. While some authors failed to 
demonstrate a significant correlation between the OCT 
parameters and MMSE scores [25, 27, 45], others have 
shown opposite results. Iseri et al. [26] were the first to 
demonstrate a significant correlation between OCT 
parameters and MMSE scores in AD patients. However, 
the correlation was significant only for the total macu-
lar volume, and not for the peripapillary RNFL thickness 
measurements. On the other hand, Ascaso et  al. [35] 
showed a significant association between RNFL thickness 
in superior and inferior quadrants, and MMSE score. 
Oktem et al. [42] also demonstrated a significant corre-
lation between MMSE scores and the RNFL parameters. 
Recently, our group confirmed a significant correlation 
between MMSE scores and several SD-OCT parameters 
[24]. For peripapillary RNFL parameters, a significant 
correlation was found for the average, superior and infe-
rior thickness. For the macular thickness, all parameters 
(except the superior and inferior outer segments) showed 
significant correlation with MMSE scores. The most sig-
nificant correlations were those of the four (superior, 
inferior, nasal and temporal) inner macular segments 
and GCL++, reflecting the most affected parameters in 
our patients. In accordance to our results, Bayhan et al. 
[43] also demonstrated a significant correlation between 
MMSE scores and macular GCL thickness. The correla-
tion between cognitive impairment and OCT parameters 
seems to be stronger for both full macular thickness and 
inner retinal layers. This is in agreement with the post 
mortem histological study in eyes of AD patients which 
demonstrated a predominantly RGC loss at the level of 
the fovea and parafoveal retina [9]. Therefore, macu-
lar thickness assessment using OCT, especially with the 
advances in high-resolution SD-OCT equipments, seems 
to be a promising diagnostic tool in AD patients. How-
ever, further studies, including earlier stages of the dis-
ease and monitoring OCT parameters changes along the 
course of the disease, are required.
Optical coherence tomography parameters in mild 
cognitive impairment
The MCI is a clinical condition in which the individual 
presents with memory loss, larger than expected for their 
age, but not enough to impair their daily activities [60]. 
The MCI can be considered as an intermediate stage 
between normal aging and dementia [61]. The amnes-
tic MCI (aMCI), a subtype with a predominant memory 
impairment, can be considered by many authors as an 
early stage of AD, mainly because the rate of progres-
sion to Alzheimer in aMCI is 10–15 % per year, while in 
normal individuals, the conversion rate is only 1–2 % per 
year [61, 62]. Since MCI may represent an earlier stage of 
dementia, before the onset of the AD, it is important that 
these patients undergo careful medical evaluation over 
the years. Monitoring the clinical status and using ancil-
lary objective tests that could document possible progres-
sion to AD are also required. In this scenario, the RNFL 
thickness and macular measurements by OCT may turn 
Fig. 1 Examples of Topcon 3D OCT‑2000 generated full‑thickness 
macular measurements in the right (OD) and left (OS) eye of a patient 
with Alzheimer’s disease. Measurements in different sectors are 
indicated with numbers and represented in colors that correspond 
to the normal distribution. Sectors in green indicate values within 
normal range; in yellow less than the 5th, in red less than the 1st com‑
pared with an age‑matched reference population. Note that several 
macular thickness parameters are below normal range, particularly in 
inner segments
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out to represent a non-invasive in vivo biological marker 
in both MCI and AD patients. Paquet et al. [34] demon-
strated that the mean peripapilary RNFL were reduced 
in both MCI and AD patients, but no significant differ-
ences were found between MCI and AD parameters. 
Similar results were also demonstrated by Oktem et  al. 
[42]. On the other hand, another group found that the 
total RNFL thickness of MCI patients was significantly 
different of both AD (thinner) and controls (thicker). The 
peripapillary RNFL loss was more pronounced in inferior 
quadrant [27]. Ascaso et  al. [35] evaluated peripapillary 
RNFL thickness and both macular thickness and volume 
in MCI patients by OCT, and also confirmed a reduc-
tion of mean RNFL thickness measurements and in all 
Fig. 2 A print out of inner macular analysis using SD‑OCT in a patient with Alzheimer disease. The built‑in viewer shows the color retinography, oct 
line scan, macular RNFL thickness (mRNFL), the ganglion cell layer + inner plexiform layer (GCL+) thickness, and the RNFL + GCL + IPL (GCL++) 
thickness. a Fundus color. The green square line demarcates the macular area scanned (7 × 7 mm) by the FD‑OCT. b Optical coherence tomography 
(vertical scan) of macular area. Center pseudo‑colored map of the measured thickness. Lower each grid in the 10 × 10 grid was color coded with no 
color (within the normal limit), yellow (outside of the 95 % normal limit), or red (outside of the 99 % normal limit)
Page 9 of 11Cunha et al. Int J Retin Vitr  (2016) 2:24 
except from the nasal quadrant when compared to con-
trols. Moreover, these authors found an apparently con-
flicting data, an increase in macular thickness parameters 
of MCI patients. They attributed this finding to possible 
inflammation and/or gliosis that would occur in the early 
stages of AD.
In a recently published study using SD-OCT, Gao 
et al. [25] found that the average thickness of the RNFL 
was reduced in MCI patients compared to AD patients 
(at inferior quadrant and segments of 5 and 6 o’clock). 
Compared to controls, MCI patients showed a significant 
reduction in RNFL thickness measurements only in the 
temporal quadrant and segments of 8, 9 and 10 o’clock. 
They also found significant reduction of the macular 
volume in MCI patients. Other authors showed that 
the RNFL thickness measurements were reduced in the 
superior quadrant and the total mean values are gradu-
ally and significantly decreased in patients ranging from 
MCI to severe AD, when compared to the controls [41]. 
In a systematic review and meta-analysis, Thomson et al. 
[39] identified five studies including 214 MCI eyes and 
421 control eyes), demonstrating a significant reduction 
Fig. 3 Example of inner macular thickness measurements by SD‑OCT of AD patient. On the left (a, c, e) represents the scanned area (7 × 7 mm). 
Each 10 × 10 grid was color coded with no color (within the normal limit), yellow (outside the 95 % normal limit), or red (outside the 99 % normal 
limit). The total analyzed area corresponding to 6 × 6 mm. On the right vertical OCT scans through the fovea. The white lines correspond to the 
boundaries of the inner retinal layers identified during the segmentation process. b Macular RNFL (mRNFL) thickness measurement, through the 
internal limiting membrane (ILM) to inner boundary of ganglion cell layer (GCL). d GCL plus inner plexiform layer (IPL), through the inner boundary 
of GCL to outer boundary of IPL (GCL+). f mRNFL plus GCL plus IPL, trough the ILM to outer boundary of IPL (GCL++)
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in the overall mean RNFL thickness and in all four quad-
rants (superior, nasal, temporal and inferior) in patients 
with MCI.
Therefore, as previously demonstrated, peripapillary 
RNFL and macular thickness parameters in MCI patients 
were significantly reduced when compared to normal 
controls. These measurements assessed by OCT dem-
onstrate that axonal loss in MCI is situated in an inter-
mediate stage between AD patients and healthy controls, 
suggesting the involvement of the retina in early phases 
even before the onset of dementia.
Conclusions
In summary, in this article we discussed several clinical 
applications of OCT in patients with AD. The peripapil-
lary RNFL thickness measurements were reduced in all 
quadrants, suggesting that a diffuse axonal degeneration 
occurs in AD patients. This finding is reinforced by the 
macular thickness reduction, especially by the loss of 
inner retinal layers, which reflects a preferential retinal 
GCL impairment in patients with AD. Therefore, OCT 
parameters can be used to distinguish AD patients from 
normal aging. Both peripapillary and macular thickness 
measurements obtained by OCT can be used to detect 
early neuronal loss as demonstrated in MCI patients, sug-
gesting that OCT could be a promising diagnostic tool in 
demential diseases. Future studies showing that OCT can 
be useful in identify the converting patients from MCI to 
AD are required. Moreover, neuronal loss seems to corre-
late well with cognitive impairment in AD, especially for 
macular parameters. This indicates the promising role of 
OCT in the clinical evaluation of these patients. There-
fore, OCT is a non-invasive test, which we believe will 
serve as a biomarker in AD patients that could be rou-
tinely used to evaluate and follow these patients, allowing 
a more comprehensive approach in this disease.
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